Skip to main content

506 IGNYTE: an open-label, multicenter, phase 1/2 (Ph 1/2) clinical trial of RP1 ± nivolumab in patients with advanced solid tumors

Publication ,  Conference
Middleton, M; Milhem, M; Aroldi, F; Sacco, J; VanderWalde, A; Baum, S; Samson, A; Chesney, J; Niu, J; Rhodes, T; Bowles, T; Emamekhoo, H ...
Published in: Journal for ImmunoTherapy of Cancer
November 2021

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Journal for ImmunoTherapy of Cancer

DOI

EISSN

2051-1426

Publication Date

November 2021

Volume

9

Issue

Suppl 2

Start / End Page

A538 / A538

Publisher

BMJ

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3204 Immunology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Middleton, M., Milhem, M., Aroldi, F., Sacco, J., VanderWalde, A., Baum, S., … Harrington, K. (2021). 506 IGNYTE: an open-label, multicenter, phase 1/2 (Ph 1/2) clinical trial of RP1 ± nivolumab in patients with advanced solid tumors. In Journal for ImmunoTherapy of Cancer (Vol. 9, pp. A538–A538). BMJ. https://doi.org/10.1136/jitc-2021-sitc2021.506
Middleton, Mark, Mohammed Milhem, Francesca Aroldi, Joseph Sacco, Ari VanderWalde, Scott Baum, Adel Samson, et al. “506 IGNYTE: an open-label, multicenter, phase 1/2 (Ph 1/2) clinical trial of RP1 ± nivolumab in patients with advanced solid tumors.” In Journal for ImmunoTherapy of Cancer, 9:A538–A538. BMJ, 2021. https://doi.org/10.1136/jitc-2021-sitc2021.506.
Middleton M, Milhem M, Aroldi F, Sacco J, VanderWalde A, Baum S, et al. 506 IGNYTE: an open-label, multicenter, phase 1/2 (Ph 1/2) clinical trial of RP1 ± nivolumab in patients with advanced solid tumors. In: Journal for ImmunoTherapy of Cancer. BMJ; 2021. p. A538–A538.
Middleton, Mark, et al. “506 IGNYTE: an open-label, multicenter, phase 1/2 (Ph 1/2) clinical trial of RP1 ± nivolumab in patients with advanced solid tumors.” Journal for ImmunoTherapy of Cancer, vol. 9, no. Suppl 2, BMJ, 2021, pp. A538–A538. Crossref, doi:10.1136/jitc-2021-sitc2021.506.
Middleton M, Milhem M, Aroldi F, Sacco J, VanderWalde A, Baum S, Samson A, Chesney J, Niu J, Rhodes T, Bowles T, Emamekhoo H, Tsai K, In G, Beasley G, Chmielowski B, Dalac-Rat S, Kahler K, Muñoz E, Olsson-Brown A, Bommareddy P, Menezes L, Pirzkall A, Coffin R, Harrington K. 506 IGNYTE: an open-label, multicenter, phase 1/2 (Ph 1/2) clinical trial of RP1 ± nivolumab in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. BMJ; 2021. p. A538–A538.

Published In

Journal for ImmunoTherapy of Cancer

DOI

EISSN

2051-1426

Publication Date

November 2021

Volume

9

Issue

Suppl 2

Start / End Page

A538 / A538

Publisher

BMJ

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3204 Immunology